Abstract Intangible Assets Pricing Model in Biotech industry In the era of knowledge-based economic, the revenue creation model of companies are transiting from conventional fixed-assets focus to new intellectual assets, brand names, and customer needs focus. Taiwan industries also jumped into this wagon and are gradually switching from the equipment manufacturers (OEM) model focused on production to a new type of model concentrated on the conjunction of technology, brand, and services. After the revision of corporation law in 2001 to stipulate that companies are allow to capitalization of their technology or goodwill, it is becomes a must to establish a well accepted pricing model for these intangible assets to the banks or industry-wide. The key of the pricing model is how to apply the valuation rules, which are commonly for the tangible assets, to the intangible assets. The pricing model will be able to act as a start point for the traders to negotiation, and decrease the transaction costs related to information non-transparence or information gathering. This paper tried to survey all the possible pricing models, regardless of theoretical and empirical ones, and make a comparison among these models. In addition, there is an analysis of market information in biotech development. At last, this paper explored some current applied pricing models by interviewing the people in the industries and using cases studies. Although there is no wide-accepted valuation l to apply, the searching as many models as possible may provide various ways to re-evaluate pricing models, and in the hope to come up a result reflected closer to the reality.